Intellipharmaceutics International Inc. (IPCI)

[AngeloFoca]

Rexista could possibly strike a death blow to Oxycontin

I wanted to write this post for several days now, but did not want to write it without the link to a very important article I had read, which is the basis of the following assumptions.

Well, I have just re-found the article and I think it's well worth reading.

http://www.latimes.com/projects/oxycontin-part1/

I'm not saying these are facts, nor probabilities... but I do think they are very high possibilities, and they make some pieces of the puzzle fit and make the picture make sense.

The condensed version of the article is basically that Oxycontin sells itself as a 2x day drug and gets premium coverage for being an extended release drug... however for many people it does not offer 12 hours of relief BUT if doctors prescribed oxycontin as 3 or 4 x a day... it would lose insurance coverage as a premium drug, so doctors are instead told to offer stronger dosages rather than more frequent doses... and there in lies the overdose issue.

When many doctors began prescribing OxyContin at shorter intervals in the late 1990s, Purdue executives mobilized hundreds of sales reps to “refocus” physicians on 12-hour dosing. Anything shorter “needs to be nipped in the bud. NOW!!” one manager wrote to her staff.
Purdue tells doctors to prescribe stronger doses, not more frequent ones, when patients complain that OxyContin doesn’t last 12 hours. That approach creates risks of its own. Research shows that the more potent the dose of an opioid such as OxyContin, the greater the possibility of overdose and death.
More than half of long-term OxyContin users are on doses that public health officials consider dangerously high, according to an analysis of nationwide prescription data conducted for The Times.

Now this is where the speculation comes in - May the reason as to why the FDA requested BE tests for Rexista, rather than a phase 3, be to monitor if Rexista shows a steady state of drug in the system throughout the 12 hour period??? and if so... might the FDA require Perdue to Re-Label their Oxycontin to perhaps 3x day... might this give Rexista a definite Best in Class label???

Purdue said in a press release they may acquire a platform this year... might they be talking about IPCI's drug delivery platform?

Personally I believe that Pfizer will partner with IPCI simply for Pfizer to get their foot in the door, in preparation for a takeover, so as not to jeopardize their Lyrica franchise in 2018... that's close to $4 billion and Regabatin is already showing itself to be better than Lyrica.